Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like W*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000381	Wockhardt USA LLC	06/30/2022	60432015016	Hydroxyzine HCL Syrup 10MG	04/29/2022	29.27	61.22	None	Non-innovator Multiple Source Drug	70000	None	Following market conditions	None	Following market conditions	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000223	Woodward Pharma Services LLC	03/31/2022	69784023120	Sodium Acetate Inj 2 mEq/ML, 100 ML, Glass Cont Qty 20	02/03/2022	173.37	300.00	None	Non-innovator Multiple Source Drug	20050	None	This increase is a result of an increase in the cost of producing the raw materials, components, manufacturing of the finished dose product, and an increase in the cost of transportation.	None	This increase is a result of an increase in the cost of producing the raw materials, components, manufacturing of the finished dose product, and an increase in the cost of transportation.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000223	Woodward Pharma Services LLC	03/31/2022	69784023020	Sodium Acetate Inj 2 mEq/ML, 50 ML, Vial Qty 20	02/03/2022	126.54	219.00	None	Non-innovator Multiple Source Drug	9889	None	This increase is a result of an increase in the cost of producing the raw materials, components, manufacturing of the finished dose product, and an increase in the cost of transportation.	None	This increase is a result of an increase in the cost of producing the raw materials, components, manufacturing of the finished dose product, and an increase in the cost of transportation.	None	None	None	None	None	None	None	None	None	None	None	None